Pharmacotherapy

  • Arthur M. Small
  • Richard Perry

Abstract

The use of drugs for the treatment of child and adolescent behavioral problems in a residential setting dates from 1937, with Bradley’s report on the beneficial effects of the stimulant drug benzedrine on the school performance and conduct of a group of 30 boys and girls, ages 5 to 14 years. Since that time, psychopharmacotherapy has become an accepted and useful treatment modality in residential and hospital settings for children and adolescents.

Keywords

Attention Deficit Hyperactivity Disorder Autistic Child Residential Treatment Stimulant Medication Conduct Disorder 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aman, M. G. (1984. Drugs and learning in mentally retarded persons. In G. D. Burrows & J. S. Werry (Eds.), Advances in human psychopharmacology (pp. 121–163). Greenwich: JAI Press.Google Scholar
  2. Anderson, L. T., Campbell, M., Grega, D. M., Perry, R., Small, A. M., & Green, W. H. (1984). Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptoms. American Journal of Psychiatry, 141, 1195–1202.PubMedGoogle Scholar
  3. Bartunkova, Z., Cerny, L. Ortilova, J., & Sturma, J. (1972). Propericiazin, diazepam, chlorpromazine and placebo in a double-blind trial in pedopsychiatric therapy. Activitas Nervosa Superior (Praha), 14, 83–84.Google Scholar
  4. Bennett, W. G., Korein, J., Kalmijn, M., Grega, D. M., & Campbell, M. (1983). EEG and treatment of hospitalized aggressive children with haloperidol or lithium. Biological Psychiatry, 18, 1427–1440.PubMedGoogle Scholar
  5. Bradley, C. (1937). The behavior of children receiving benzedrine. American Journal of Psychiatry, 94, 577–585.Google Scholar
  6. Cade, J. F. J. (1949). Lithium salts in the treatment of psychotic excitement. Medical Journal of Australia, 36, 349–352.Google Scholar
  7. Campbell, M., Adams, P., Small, A. M., Tesch, L. M., & Curren, E. L. (1988). Naltrexone in infantile autism. Psychopharmacology Bulletin, 24, 135–139.PubMedGoogle Scholar
  8. Campbell, M., Anderson, L. T., Cohen, I. L., Perry, R., Small, A. M., Green, W. H., Anderson, L., & McCandless, W. (1982). Haloperidol in autistic children: Effects on learning, behavior and abnormal involuntary movements. Psychopharmacology Bulletin, 18, 110–112.Google Scholar
  9. Campbell, M., Anderson, L. T., Small, A. M., Perry, R., Green, W. H., & Caplan, R. (1982). The effects of haloperidol on learning and behavior in autistic children. Journal of Autism and Developmental Disorders, 12, 167–175.PubMedCrossRefGoogle Scholar
  10. Campbell, M., Cohen, I., & Perry, R. (1983. Psychopharmacological treatment. In T. H. Ollendick & M. Hersen (Eds.), Handbook of child psychopathology (pp. 461–484). New York: Plenum Press.CrossRefGoogle Scholar
  11. Campbell, M., Cohen, I. L., Perry, R., & Small, A. M. (in press). Psychopharmacological treatment. In T. H. Ollendick & M. Hersen (Eds.), Handbook of child psychopathology. New York: Plenum Press.Google Scholar
  12. Campbell, M., Cohen, I. L., & Small, A. M. (1982). Drugs in aggressive behavior. Journal of the American Academy of Child Psychiatry, 21, 107–117.PubMedCrossRefGoogle Scholar
  13. Campbell, M., Geller, B., & Cohen, I. L. (1977). Current status of drug research and treatment with autistic children. Journal of Pediatric Psychology, 2, 153–161.CrossRefGoogle Scholar
  14. Campbell, M., Green, W. H., & Deutsch, S. I. (1985). Child and adolescent psychopharmacology. Beverly Hills: Sage.Google Scholar
  15. Campbell, M., Grega, D. M., Green, W. H., & Bennett, W. G. (1983). Neuroleptic-induced dyskinesias in children. Clinical Neuropharmacology, 6, 207–222.PubMedCrossRefGoogle Scholar
  16. Campbell, M., Perry, R., & Green, W. H. (1984). Use of lithium in children and adolescents. Psychosomatics, 25, 95–106.PubMedCrossRefGoogle Scholar
  17. Campbell, M., Small, A. M., Green, W. H., Jennings, S. J., Perry, R., Bennett, W. G., & Anderson, L. (1984). Behavioral efficacy of haloperidol and lithium carbonate: A comparison in hospitalized aggressive children with conduct disorder. Archives of General Psychiatry, 41, 650–656.PubMedCrossRefGoogle Scholar
  18. Campbell, M., Small, A. M., Palij, M., Perry, R., Polonsky, B. B., Lakashok, D., & Anderson, L. T. (1987). The efficacy and safety of fenfluramine in autistic children: Preliminary analysis of a double-blind study. Psychopharmacology Bulletin, 23, 123–127.PubMedGoogle Scholar
  19. Cohen, D. J., Shaywitz, B. A., Young, J. G., Carbonari, C.M., Nathanson, J. A., Lieberman, D., Bowers, M. B., & Mass, J. W. (1979). Central biogenic amine metabolism in children with the syndrome of chronic multiple tics of Gilles de la Tourette. Journal of the American Academy of Child Psychiatry, 18, 320–341.PubMedCrossRefGoogle Scholar
  20. Comings, D. E., & Comings, B. G. (1984). Tourette’s syndrome and attention deficit with hyperactivity: Are they genetically related? Journal of the American Academy of Child Psychiatry, 23, 138–146.PubMedCrossRefGoogle Scholar
  21. Connell, P. H., Corbett, J. A., Home, D. J., & Mathews, A. M. (1967). Drug treatment of adolescent tiguers: A double-blind trial of diazepam and haloperidol. British Journal of Psychiatry, 113, 375–381.PubMedCrossRefGoogle Scholar
  22. Conners, C. K. (1969). A teacher rating scale for use in drug studies with children. American Journal of Psychiatry, 126, 152–156.Google Scholar
  23. Conners, C. K. (1985). Issues in the study of adolescent ADD-H/hyperactivity. Psychopharmacology Bulletin, 21, 243–250.PubMedGoogle Scholar
  24. Conners, C. K., Kramer, R., Rothschild, G. H., Schwartz, L., & Stone, A. (1971). Treatment of young delinquent boys with diphenylhydantoin sodium and methylphenidate: A controlled comparison. Archives of General Psychiatry, 24, 156–162.PubMedCrossRefGoogle Scholar
  25. Conners, C. K., & Taylor, E. (1980). Pemoline, methylphenidate, and placebo in children with minimal brain dysfunction. Archives of General Psychiatry, 21, 182–190.CrossRefGoogle Scholar
  26. Cunningham, M. A., Pillai, V., & Rogers, W. J. B. (1968). Haloperidol in the treatment of children with severe behavior disorders. British Journal of Psychiatry, 114, 845–854.PubMedCrossRefGoogle Scholar
  27. D’Amato, G. (1962). Chlordiazepoxide in management of school phobia. Diseases of the Nervous System, 23, 292–295.PubMedGoogle Scholar
  28. DeLong, G. R., & Aldershof, A. L. (1987). Long-term experience with lithium treatment in childhood: Correlation with clinical diagnosis. Journal of the American Academy of Child and Adolescent Psychiatry, 26, 389–394.PubMedCrossRefGoogle Scholar
  29. DeLong, G. R., & Nieman, G. W. (1983). Lithium-induced behavior changes in children with symptoms suggesting manic-depressive illness. Psychopharmacology Bulletin, 19, 258–265.PubMedGoogle Scholar
  30. Denckla, M. B., Bemporad, J. R., & MacKay, M. C. (1976). Tics following methylphenidate administration: A report of 20 cases. Journal of the American Medical Association, 235, 1349–1351.PubMedCrossRefGoogle Scholar
  31. Deutsch, S.I. (1986a). Managing behavior in mentally retarded residential populations. Hospital and Community Psychiatry, 37, 221–222.PubMedGoogle Scholar
  32. Deutsch, S.I. (1986b). Rationale for the administration of opiate antagonists in treating infantile autism. American Journal of Mental Deficiency, 90, 631–635.PubMedGoogle Scholar
  33. Evans, B. W., Clay, T. H., & Gualtieri, T. (1987). Carbamazepine in pediatric psychiatry. Journal of the American Academy of Child and Adolescent Psychiatry, 26, 2–8.PubMedCrossRefGoogle Scholar
  34. Geller, B., & Greydanus, B. E. (1979). Haloperidol-induced comatose state with hyperthermia and rigidity in adolescence: Two case reports and a literature review. Journal of Clinical Psychiatry, 40, 102–103.PubMedGoogle Scholar
  35. Gittelman, R., & Mannuzza, S. (1985). Diagnosing ADD-H in adolescents. Psychopharmacology Bulletin, 21, 237–242.PubMedGoogle Scholar
  36. Gittelman-Klein, R., & Klein, D. F. (1973). School phobia: Diagnostic considerations in the light of imipramine effects. Journal of Nervous and Mental Disease, 156, 199–215.PubMedCrossRefGoogle Scholar
  37. Gittelman-Klein, R., Klein, D. F., Katz, S., Saraf, K. R., & Pollack, E. (1976). Comparative effects of methylphenidate and thioridazine in hyperkinetic children: I. Clinical results. Archives of General Psychiatry, 33, 1217–1231.PubMedCrossRefGoogle Scholar
  38. Glick, B. S., Schulman, D., & Turecki, S. (1971). Diazepam (Valium) treatment in childhood sleep disorders. Diseases of the Nervous System, 32, 565–566.PubMedGoogle Scholar
  39. Green, W. H., Campbell, M., Wolsky, B. B., Deutsch, S. I., Golden, R. R., & Cicero, S. D. (October, 1984). Effects of short and long term haloperidol administration on growth in young autistic children. Paper presented at the 31st Annual Meeting of the American Academy of Child Psychiatry, Toronto.Google Scholar
  40. Greenblatt, D. J., & Shader, B. I. (1974). Benzodiazepines in clinical practice. New York: Raven Press.Google Scholar
  41. Greenhill, L. L., Rieder, R. O., Wender, P. H., Buchsbaum, M., & Zahn, T. P. (1973). Lithium carbonate in the treatment of hyperactive children. Archives of General Psychiatry, 28, 636–640.PubMedCrossRefGoogle Scholar
  42. Gualtieri, C. T., Quade, D., Hicks, R. E., Mayo, J. P., & Schroeder, S. R. (1984). Tardive dyskinesia and other clinical consequences of neuroleptics treatment in children and adolescents. American Journal of Psychiatry, 141, 20–23.PubMedGoogle Scholar
  43. Herman, B. H., Hammock, M. K., Arthur-Smith, A., Egan, J., Chatoor, I., Zelnick, N., Appelgate, K., Beockx, R. L. (1986). Effects of naltrexone in autism: Correlation with plasma opioid concentrations. Scientific Proceedings for the Annual Meeting of the American Academy of Child and Adolescent Psychiatry, 2, 11–12.Google Scholar
  44. Kline, A. H. (1968). Diazepam and the management of nocturnal enuresis. Clinical Medicine, 75, 20–22.Google Scholar
  45. Kraft, I. A., Ardali, C., Duffy, J. H., Hart, J. T., & Pearce, P. (1965). A clinical study of chlordiazepoxide used in psychiatric disorders of children. International Journal of Neuropsychiatry, 1, 433–437.PubMedGoogle Scholar
  46. Krakowski, A. J. (1963). Chlordiazepoxide in treatment of children with emotional disturbances. New York State Journal of Medicine, 63, 3388–3392.PubMedGoogle Scholar
  47. Lefkowitz, M. M. (1969). Effects of diphenylhydantoin on disruptive behavior. Archives of General Psychiatry, 20, 643–651.PubMedCrossRefGoogle Scholar
  48. Levenson, J. L. (1985). Neuroleptic malignant syndrome. American Journal of Psychiatry, 142, 1137–1145.PubMedGoogle Scholar
  49. Lowe, T. L., Cohen, D. J., Detlor, J., Kremenitzer, M. W., & Shaywitz, B. A. (1982). Stimulant medications precipitate Tourette’s syndrome. Journal of the American Medical Association, 247, 1729–1731.PubMedCrossRefGoogle Scholar
  50. Lucas, A. R., & Pasley, F. C. (1969). Psychoactive drugs in treatment of emotionally disturbed children: Haloperidol and diazepam. Comprehensive Psychiatry, 10, 376–386.PubMedCrossRefGoogle Scholar
  51. Mattes, J., & Gittelman, R. (1983). Growth of hyperactive children on maintenance methylphenidate. Archives of General Psychiatry, 40, 317–321.PubMedCrossRefGoogle Scholar
  52. McNutt, B. A., Boileau, R. A., Cohen, M. N., Sprague, R. L., & von Neumann, A. (May, 1976). The effects of long term stimulant medication on the growth and body composition of hyperactive children: II. Report on 2 years. Paper presented at the Annual Early Clinical Drug Evaluation Unit Meeting, Psychopharmacology Research Branch, National Institute of Mental Health, Key Biscayne, FL.Google Scholar
  53. Panksepp, J., & Sahley, T. L. (1987. Possible brain opioid involvement in disrupted social intent and language development in autism. In E. Schopler & G. B. Mesibov (Eds.), Neurobiological issues in autism (pp. 357–372). New York: Plenum Press.Google Scholar
  54. Perry, R., Campbell, M., Adams, P., Lynch, N., Spencer, E. K., Curren, E. L., & Overall, S. E. (1989). Long-term haloperidol in autistic children: Continuous vs. discontinuous drug administration. Journal of the American Academy of Child and Adolescent Psychiatry, 28, 87–92.PubMedCrossRefGoogle Scholar
  55. Perry, R., Campbell, M., Green, W. H., Small, A. M., Die Trill, M. L., Meiselas, K., Golden, R. R., & Deutsch, S. I. (1985). Neuroleptic-related dyskinesias in autistic children: A prospective study. Psychopharmacology Bulletin, 21, 140–143.PubMedGoogle Scholar
  56. Pesikoff, R. B., & Davis, P. C. (1971). Treatment of pavor nocturnus and somnambulism in children. American Journal of Psychiatry, 128, 778–781.PubMedGoogle Scholar
  57. Petti, T. A., & Campbell, M. (1975). Imipramine and seizures. American Journal of Psychiatry, 132, 538–540.PubMedGoogle Scholar
  58. Petti, T. A., Fish, B., Shapiro, T., Cohen, I. L., & Campbell, M. (1982). Effects of chlordiazepoxide in disturbed children: A pilot study. Journal of Clinical Psychopharmacology, 2, 270–273.PubMedGoogle Scholar
  59. Physicians Desk Reference. (1989). Oradell, NJ: Medical Economics Company.Google Scholar
  60. Platt, J. E., Campbell, M., Green, W. H., & Grega, D. M. (1984). Cognitive effects of lithium carbonate and haloperidol in treatment-resistant aggressive children. Archives of General Psychiatry, 41, 657–662.PubMedCrossRefGoogle Scholar
  61. Pliszka, S. (1987). Tricyclic antidepressants in the treatment of children with attention deficit disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 26, Mini.Google Scholar
  62. Polakoff, S. A., Sorgi, P. J., & Ratey, J. J. (1986). The treatment of impulsive and aggressive behavior with nadolol. Journal of Clinical Psychopharmacology, 6, 125–126.PubMedCrossRefGoogle Scholar
  63. Pool, D., Bloom, W., Mielke, D. H., Roniger, J. J., & Gallant, D. M. (1976). A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients. Current Therapeutic Research, 19, 99–104.PubMedGoogle Scholar
  64. Pouissant, A. F., & Ditman, K. S. (1965). A controlled study of imipramine (Tofranil) in the treatment of childhood enuresis. Journal of Pediatrics, 67, 283–290.CrossRefGoogle Scholar
  65. Puig-Antich, J., Perel, J. M., Lupatkin, W., Chambers, W. J., Tabrizi, M. A., King, J., Goetz, R., Davies, M., & Stiller, R. L. (1987). Imipramine in prepubertal major depressive disorders. Archives of General Psychiatry, 44, 81–89.PubMedCrossRefGoogle Scholar
  66. Rapoport, J. L., Buchsbaum, M. S., Weingartner, H., Zahn, T. P., Ludlow, C., & Mikkelsen, E. J. (1980). Dextroamphetamine: Its cognitive and behavioral effects in normal and hyperactive boys and normal men. Archives of General Psychiatry, 37, 933–943.PubMedCrossRefGoogle Scholar
  67. Rapoport, J. L., Mikkelsen, E. J., & Werry, J. S. (1978). Antimanic, antianxiety, hallucinogenic and miscellaneous drugs. In J. S. Werry (Ed.), Pediatric psychopharmacology: The use of behavioral modifying drugs in children (pp. 316–355). New York; Brunner/Mazel.Google Scholar
  68. Rapoport, J. L., Mikkelsen, E. J., Zavadil, A., Nee, L., Gruenau, C., Mendelson, W., & Gillin, J. C. (1980). Childhood enuresis: II. Psychopathology, tricyclic concentration in plasma and antienuretic effect. Archives of General Psychiatry, 37, 1146–1152.PubMedCrossRefGoogle Scholar
  69. Ratey, J. J., Mikkelson, E., Sorgi, P., Zuckerman, S., Polakoff, S., Bemporad, J., Bick, P., & Kadish, W. (1987). Autism: The treatment of aggressive behaviors. Journal of Clinical Psychopharmacology, 7, 35–41.PubMedGoogle Scholar
  70. Realmuto, G. M., Erickson, W. D., Yellin, A. M., Hopwood, J. H., & Greenberg, L. M. (1984). Clinical comparison of thiothixene and thioridazine in schizophrenic adolescents. American Journal of Psychiatry, 14, 440–442.Google Scholar
  71. Ritvo, E. R., Freeman, B. J., Yuwiler, A., Geller, E., Schroth, P., Yokota, A., Mason-Brothers, A., August, G. J., Klykylo, W., Leventhal, B., Lewis, K., Piggott, L., Realmuto, G., Stubbs, E. G., & Umansky, R. (1986). Fenfluramine treatment of autism: UCLA collaborative study of 81 patients at nine medical centers. Psychopharmacology Bulletin, 22, 133–140.PubMedGoogle Scholar
  72. Rogers, W. J. B. (1965). Use of haloperidol in children’s psychiatric disorders. Clinical Trials Journal, 2, 162–165.Google Scholar
  73. Satterfield, J. H., Cantwell, D. P., Schell, A., & Blaschke, T. (1979). Growth of hyperactive children treated with methylphenidate. Archives of General Psychiatry, 36, 212–217.PubMedCrossRefGoogle Scholar
  74. Shapiro, A. K., Shapiro, E., & Wayne, H. (1973). Treatment of Tourette’s syndrome. Archives of General Psychiatry, 28, 92.PubMedCrossRefGoogle Scholar
  75. Sheard, M. H. (1975). Lithium in the treatment of aggression. Journal of Nervous and Mental Disease, 160, 108–118.PubMedCrossRefGoogle Scholar
  76. Sheard, M. H., Marini, J. L., Bridges, C. I., & Wagner, E. (1976). The effects of lithium on impulsive, aggressive behavior in man. American Journal of Psychiatry, 133, 1409–1413.PubMedGoogle Scholar
  77. Siassi, I. (1982). Lithium treatment of impulsive behavior in children. Journal of Clinical Psychiatry, 32, 34–42.Google Scholar
  78. Simpson, G. M., Lee, J. H., Zoubok, B., & Gardos, G. (1979). A rating scale of tardive dyskinesia. Psychopharmacology (Berlin), 64, 171–179.CrossRefGoogle Scholar
  79. Wender, P. H., Wood, D. R., & Reimirer, F. W. (1985). Pharmacological treatment of attention deficit disorder, residual type (ADD, RT, “minimal brain dysfunction,” “hyperactivity”) in adults. Psychopharmacology Bulletin, 21, 222–227.PubMedGoogle Scholar
  80. Werry, J. S., & Aman, M. G. (1975). Methylphenidate and haloperidol in children: Effects on attention, memory and activity. Archives of General Psychiatry, 32, 790–795.PubMedCrossRefGoogle Scholar
  81. Werry, J. S., Weiss, G., Douglas, V., & Martin J. (1966). Studies on the hyperactive child: III. The effects of chlorpromazine upon behavior and learning ability. Journal of the American Academy of Child Psychiatry, 5, 292–312.PubMedCrossRefGoogle Scholar
  82. Williams, D. T., Mehl, R., Yudofsky, S., Adams, D., & Roseman, B. (1982). The effects of propranolol on uncontrolled rage outbursts in children and adolescents with organic brain dysfunction. Journal of the American Academy of Child Psychiatry, 21, 129–135.PubMedCrossRefGoogle Scholar
  83. Wong, G. H., & Cock, P. J. (1971). Long-term effects of haloperidol on severely emotionally disturbed children. Australian and New Zealand Journal of Psychiatry, 5, 296–300.PubMedCrossRefGoogle Scholar
  84. Zesiewicz, M. F., Natta, M. B., & Kupst, M. J. (1987). Effects of psychiatric hospitalization and psychotropic medications on weight in children. Journal of the American Academy of Child and Adolescent Psychiatry, 26, 854–857.PubMedCrossRefGoogle Scholar
  85. Zrull, J. P., Westman, J. C., Arthur, B., & Bell, W. A. (1963). A comparison of chlordiazepoxide, d-amphetamine, and placebo in the treatment of the hyperkinetic syndrome in children. American Journal of Psychiatry, 120, 590–591.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • Arthur M. Small
    • 1
  • Richard Perry
    • 2
  1. 1.Department of PsychiatryNew York University Medical CenterNew YorkUSA
  2. 2.Bellevue Hospital Center and Department of PsychiatryNew York University Medical CenterNew YorkUSA

Personalised recommendations